British Gene and Cell therapy (BGCT)

 

27 April, London

Lentviral and retroviral vectors are at the forefront of advanced therapeutic medicinal product (ATMP) development. The 1-day conference in April 2018 aims to give the attendee an overview about the successes, challenges and areas for future development. The programme is exciting and key national and international speakers including Claire Booth and Luigi Naldini have accepted the invitation to speak at the conference. The annual Fairbairn Award will give students and early post-docs the chance to compete for the prestigious Fairbairn Award. The conference will close with a moderated questions and answers session, debating the pros and cons of gene editing versus gene addition-based strategies.